Format

Send to

Choose Destination
Top Antivir Med. 2016 May-Jun;24(1):59-81.

CROI 2016: Advances in Antiretroviral Therapy.

Author information

1
University of Texas Health Science Center, San Antonia, TX, USA.
2
Columbia University Medical Center, New York, NY, USA.
3
Columbia University Medical Center and New York Blood Center, New York, NY, USA.
4
Weill Cornell Medicine, New York, NY, USA.

Abstract

The 2016 Conference on Retroviruses and Opportunistic Infections highlighted exciting advances in antiretroviral therapy, including important data on investigational antiretroviral drugs and clinical trials. Clinical trials demonstrated benefits from a long-acting injectable coformulation given as maintenance therapy, examined intravenous and subcutaneous administration of a monoclonal antibody directed at the CD4 binding site of HIV-1, and provided novel data on tenofovir alafenamide. Several studies focused on the role of HIV drug resistance, including the significance of minority variants, transmitted drug resistance, use of resistance testing, and drug class-related resistance. Novel data on the HIV care continuum in low- and middle-income settings concentrated on differentiated HIV care delivery models and outcomes. Data on progress toward reaching World Health Organization 90-90-90 targets as well as outcomes related to expedited initiation of HIV treatment and adherence strategies were presented. Results from a trial in Malawi showed reduced rates of mother-to-child transmission among HIV-infected women who initiated antiretroviral therapy prior to pregnancy, and several studies highlighted the effect of antiretroviral therapy in pediatric populations. A special session was dedicated to the findings of studies of Ebola virus disease and treatment during the outbreak in West Africa.

PMID:
27398863
PMCID:
PMC6148924
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for IAS-USA Icon for PubMed Central
Loading ...
Support Center